



**Expedited Clinical Programs and Study Designs for Osteoarthritis Structure Modifying Therapies
May 16, 2019
Washington, DC**

Draft Program Agenda

9:00 – 9:15 AM	Welcome & Overview Joel Block, MD
9:15 – 9:45 AM	Panel Discussion: Impact of OA Prevalence, risk factors, societal burden, unmet need Leigh Callahan, PhD; Tuhina Neogi, MD, PhD; patient representative
9:45 – 10:00 AM	Group Discussion Moderator: Jeffrey Katz, MD
10:00 – 10:15 AM	Break
10:15 – 10:45 AM	Disease progression Current status of imaging biomarkers Philip Conaghan, MD, PhD
10:45 – 11:00 AM	Current status of soluble biomarkers for OA Virginia Kraus, MD
11:00 – 11:30 AM	Group Discussion Panel: Philip Conaghan, MD; Virginia Kraus, MD Moderator: Joel Block, MD
11:30 AM – 12:00 PM	Applying biomarkers for accelerated approval of OA structure modifying drugs Nikolay Nikolov, MD Food and Drug Administration (FDA)
12:00 – 12:30 PM	Group Discussion Moderator: Marc Hochberg, MD, MPH
12:30 – 1:15 PM	Lunch
1:15 – 2:15 PM	Post approval study designs for drugs approved on the basis of a surrogate endpoint in OA Lee Simon, MD
2:15– 3:30 PM	Group Discussion Moderator: Philip Conaghan, MD, PhD
3:30 – 3:45 PM	Final comments Joel Block, MD

